Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell c...
Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, ...
Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma ( Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, Nashville, USA )
26 Feb 2021
SEMS trial: result of a prospective, multi-institutional phase II clinical trial...
Dr Sia Daneshmand - University of Southern California, Los Angeles, USA
SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma ( Dr Sia Daneshmand - University of Southern California, Los Angeles, USA )
24 Feb 2021
Challenges in nursing GU cancer patients during COVID-19
Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK
Challenges in nursing GU cancer patients during COVID-19 ( Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK )
24 Feb 2021
Latest developments in the treatment of mRCC
Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald
Latest developments in the treatment of mRCC ( Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald )
24 Feb 2021
Long term response to apalutamide and other updates impacting patients with nmCR...
Prof Axel Merseburger and Prof Matthew Smith
Long term response to apalutamide and other updates impacting patients with nmCRPC from ASCO GU 2021 ( Prof Axel Merseburger and Prof Matthew Smith )
22 Feb 2021
mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early t...
Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt A...
mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early treatment? ( Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt Attard )
19 Feb 2021
Diagnosis, testing and biomarkers in the individualisation of patient care with ...
Prof Andrea Necchi and Prof Eva Compérat
Diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer ( Prof Andrea Necchi and Prof Eva Compérat )
18 Feb 2021
Nurse's perspective on PARP inhibitors and personalised medicine in prostate can...
Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK
Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer ( Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK )
17 Feb 2021
TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alte...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
15 Feb 2021
ASCO GU 2021: Renal cancer roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2021: Renal cancer roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
15 Feb 2021
TITAN: Update and where next for patients with hormone sensitive PC
Prof Axel Merseburger and Prof Kim Chi
TITAN: Update and where next for patients with hormone sensitive PC ( Prof Axel Merseburger and Prof Kim Chi )
15 Feb 2021
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
15 Feb 2021